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SINCE the introduction of thiopentone as an intravenous anaesthetic in 1934, it
has been realised that the drug is not completely satisfactory for all types of
patients and different durations of surgery. Certain difficulties have been overcome
by the realization that by using smaller doses the toxicity is reduced to a minimum.
However, the fact remains that while anaesthesia is short, recovery results because
the drug is stored away in muscle to be released slowly over many hours. This
makes it unsatisfactory for outpatients and even patients in hospital often remain
drowsy for long periods after the operation unless therei is pain or discomfort.
Search for a shorter acting drug led to the synthesis of methohexitone (Brietal)
and in many ways it is ideal for outpatients, both dental and those for minor
surgery. However even this drug is not rapidly broken but stored up in the body
to some extent, and there is cumulation on repeated dosage (Clarke and Dundee,
1966). It has also the drawback that excitatory effects (twiching, hiccough, etc.)
occur, though their incidence can be reduced by slow injection and opiate pre-
medication (Dundee et al, 1961).
Of the non-barbiturates tested, propanidid is the first short-acting drug to pass
the rigorous clinical trials. It has been shown to produce few excitatory effects,
little hypotension, and recovery is as rapid as one could want (Dundee and Clarke,
1964). It is sufficiently insoluble in water to necessitate the use of a "solubilizing
agent", and is available as a 5 per cent solution, which remains stable for over
two years. Its value is marred by the viscosity of the solution, the prolongation
of the action of suxamethonium and a higher incidence of postoperative sickness
than follows the use of barbiturates. In order to assess the usefulness of the drug
and the general validity of the above conclusions it was decided to carry out a
group trial.
ORGANISATION OF THE TRIAL
For this study a number of practising anaesthetists of varying seniority and
experience were asked to participate. Each was given a minimum of 20 half-
gramme ampoules of the drug and a brief factual summary of its pharmacology.
They were asked to use it in their routine practise in place of thiopentone or
methohexitone. On completion of the study each was asked to fill in a question-
naire comparing propanidid with the barbiturates. Completed questionnaires, often
with detailed reports, were received from 66 anaesthetists, covering 1402 anaesthetics
for a wide variety of surgery (Table I).
44TABLE I
Grade of anaesthetist participating in the group study (absolute
numbers of each type of surgical case anaesthetised by them.
Seniority of anaesthetist
Major surgery in-all fields
Minor Inpatients
Outpatients
Obstetrics ...... ...
E.N.T. and I.P. Dentals
Paediatrics
E.C.T. . .....
Total numbers ....
Consultant and S.H.M.O.
Senior Registrar ...
Registrar and J.H.M.O.
S.H.O.
Induction
only
422
364
...... 151
19
...... 115
...... 50
~ 1121
The participants were asked to express a preference with regard to various
properties and actions, also whether they thought the drug was likely to be of
clinical use. If the answer to the latter question was "yes", they were to suggest
likely fields of usefulness. Finally, they were asked about difficulties encountered,
particularly those met in certain techniques or types of procedures.
RESULTS
The results from the specific questions (Table II) indicate that in the dosage
used (4-6 mg/kg was recommended) propanidid was preferred with regard to
cardiovascular and respiratory depression by most people. Recovery was almost
TABLE II
Answers to specific questions on propanidid. Figures
anaesthetists.
Action compared with thiopentone
Cardiovascular depression
Respiratory depression ......
Recovery
Physical properties
Postoperative vomiting
Propanidid
preferred
48
47
92
2
5
General opinion of the drug
Likely to be of clinical use
Unlikely to be of clinical use
Future uncertain
refer to percentages of
Thiopentone
preferred
11
15
0
80
36
No
prefeence
41
38
8
18
59
73
9
18
45
figures) and
35
6
13
12
66
Sole
Agent
23
61
92
176
Main
Agent
15
70
18
2
105universally found to be more rapid after propanidid. On the other hand it was
not popular because of its physical properties. The opinions about vomiting were
more equivocal, because the majority of participants found no difference in its
incidence but of those who did, most people found that thiopentone was less emetic.
The overall opinion of the drug was that it was likely to have a place in clinical
use. Of the 48 taking this view 45 mentioned out-patients specifically, 25 mentioned
minor in-patients and 4 suggested its use for "poor risk" patients.
The objections to the drug though expressed in many different ways can be
classified as in Table III. The largest group encountered was due to its viscosity,
which made injection difficult. As one would expect from a short acting drug,
there was difficulty in attaining smooth surgical anaesthesia because of the slow
uptake of the volatile supplement. Other less common objections are also given in
the table.
TABLE III
Percentage incidence of the major difficulties reported by the anaesthetists in
the trial.
Objections to the viscosity, "oiliness" or to the necessity for using a
large needle ..... ...... ...... ...... ...... ...... . .....57
Difficulty in take over of inhalation agent owing to brevity of action 41
Postoperative sickness ...... ...... ...... ...... ..... ......... 27
Prolongation of action of suxamethonium leading to problems .... 19
Excitatory phenomena (muscle movements) .............. ..... .... .. 14
Hypotension with large doses or in ill patients ...... ...... ...... ..... 8
DISCUSSION
The method of group trial gives an opportunity of finding out early in the life
of a drug whether anaesthetists would really want to use it. The answers to the
specific questions must be judged in the light of the information already supplied
to the anaesthetists, which may have influenced some of them. There was a high
incidence of "no preference" answers to three of the questions. Where there was a
definite comment about the rapid recovery, the participant was not asked whether
this was a good thing for the patient and some expressed views to the contrary,
except for out-patients. The rapidity of recovery led to the difficulty in take over
of an inhalation agent (Table III) but this can be overcome with practise.
The physical properties of the agent were mentioned frequently in the general
reports of difficulties encountered. The oiliness, tendency to form bubbles and
necessity for use of a large needle were all unpopular. The latter is a particular
difficulty with children but can be overcome by diluting the drug from a 5 per
cent to a 3.5 per cent solution. A less viscous preparation is on trial at present
and seems very similar in its other properties to the older solution, except that it
can be injected through a 23 s.w.g. (No. 12) needle with acceptable speed. Against
these objections, a drug in solution has advantages over the barbiturates, which
are only stable in powder form.
46The high incidence of postoperative vomiting after propanidid has been noted
by Dundee, Kirwan and Clarke (1965) and by Goldman and Kennedy (1964) but
many general surveys of its use have not mentioned this complication (Howells
et al, 1964; Swerdlow, 1965; Gunner et al, 1965). Certainly the majority of the
sickness is in the first hour after the drug and if atropine premedication alone is
used, there is little late nausea or vomiting.
The difficulties mentioned spontaneously included prolongation of the action of
suxamethonium. For most work this action presents no problems but during
bronchoscopy and electro-convulsive therapy, where nitrous oxide is not normally
used, the patient may regain consciousness before the relaxant has worn off. This
is particularly unfortunate in E.C.T. where the other properties of the drug would
have made it very useful.
A high incidence of spontaneous muscle movements have not been encountered
by the authors using optimal dosage (4-6 mg/kg) but higher doses or very rapid
injection, increase the incidence of these complications. Certainly the use of large
doses is no substitute for a technique of rapid administration of inhalation agents
after intravenous induction. Some anaesthetists also found hypotension common
after the use of large doses and in ill patients. With such it is particularly essential
to have a smooth "take over" after the induction and the injection of tubocurarine
immediately before the propanidid in major surgery does achieve this result. In
low dosage the drug has less cardiovascular toxicity than thiopentone and could
be used for poor-risk cases though it is doubtful whether this is a specific indication.
Many of the anaesthetists who suggested using the drug for outpatients had not
themselves used it for this purpose but all of those who had (25) were satisfied
with its action. As sole agent for the extraction of 1-2 teeth and for the rapid
incision of an abscess the drug is ideal and as main agent for slightly larger pro-
cedures it is satisfactory. Another field where the rapid recovery is most valuable
is in the electrical conversion of cardiac arrythmias where even if a second shock
is necessary the duration of sleep just matches the duration of the procedure. No
premedication is necessary and in this field as with most outpatients where the
drug was used vomiting has been very rare.
SUMMARY
A group trial of the new intravenous anaesthetic, propanidid, is described in
which 66 anaesthetists took part. The main difficulties encountered with the pre-
paration were its high viscosity, its brief action and, less consistently, early
postoperative vomiting. Now that a less viscous preparation is available it would
appear that the drug has a definite place for outpatient and brief in-patient
anaesthesia.
ADDENDUM
Since this study was completed the less viscous form of propanidid has been
marketed in the name of Epontol. The lesser viscosity probably affects the clinical
acceptability of the drug.
We would like to thank all the anaesthetists who took part in the trial, and Dr. Donald
Whitfield of Farbenfabriken Bayer AG for generous supplies of propanidid.
47REFERENCES
CLARKE, R. S. J. and DUNDEE, J. W. (1966). Brit. J. Anaesth., 38, 401.
DUNDEE, J. W. and CLARKE, R. S. J. (1964). Brit. J. Anaesth., 36, 100.
DUNDEE, J. W., KIRWAN, M. J. and CLRKE, R. S. J. (1965). Acta anaesth. Scandinav., 9, 223.
DUNDIE. J. W., RIDING, J. E., BARRON, D. W. and NICHOLL, R. M. (1961). Brit. J. Anaesth.,
33, 296.
GOLDMAN, V. and KENNEDY, P. (1964). Anaesthesia, 19, 424.
GUNNER, B. W., HARRISON, G. A. and WALKER, W. D. (1965). Med. J. Aust. 2, 327.
HowELLs, T. H., ODELL, J. R., HAWKINS, T. J. and STEANE, P. A. (1964). Brit. J. Anaesth.,
36, 295.
SWERDLOW, M. (1965). Brit. J. Anaesth., 37, 785.
48